These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 19383823)

  • 1. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
    Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
    Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
    Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
    Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G
    J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
    Wang ZX; Xue D; Liu ZL; Lu BB; Bian HB; Pan X; Yin YM
    Int J Biochem Cell Biol; 2012 Jan; 44(1):200-10. PubMed ID: 22064247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
    Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
    Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selectivity-determining residues in Plk1.
    Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
    Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
    Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
    Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity.
    Morales AG; Brassesco MS; Pezuk JA; Oliveira JC; Montaldi AP; Sakamoto-Hojo ET; Scrideli CA; Tone LG
    Anticancer Drugs; 2011 Nov; 22(10):995-1001. PubMed ID: 21822121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
    Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
    Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
    J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
    Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM
    Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLK1 inhibitors: setting the mitotic death trap.
    Plyte S; Musacchio A
    Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
    Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
    Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
    Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
    Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.